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AIMS
Evidence for drug use in newborns is sparse, which may cause large differences in drug prescriptions. We aimed to investigate the
differences between neonatal intensive care units (NICUs) in the Netherlands in currently prescribed drugs.
METHODS
This multicentre study included neonates admitted during 12months to four different NICUs. Drugs were classiﬁed in accordance
with the Anatomical Therapeutic Chemical (ATC) classiﬁcation system and assessed for on/off-label status in relation to neonatal
age. The treatment protocols for four common indications for drug use were compared: pain, intubation, convulsions and
hypotension.
RESULTS
A total of 1491 neonates (GA range 23+6–42+2 weeks) were included with a total of 32 182 patient days, 181 different drugs and
10 895 prescriptions of which 23% was off-label in relation to neonatal age. Overall, anti-infective drugs were most frequently
used with a total of 3161 prescriptions, of which 4% was off-label in relation to neonatal age. Nervous system drugs included
2500 prescriptions of which 31% was off-label in relation to neonatal age. Nervous system drugs, blood and blood forming
organs, and cardiovascular drugs showed the largest differences between NICUs with ranges of 919–2278, 554–1465, and
238–952 total prescriptions per 1000 patients per ATC class, respectively.
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CONCLUSIONS
We showed that drug use varies widely in neonatal clinical practice. The drug classes with the highest proportion of off-label drugs
in relation to neonatal age showed the largest differences between NICUs, i.e. cardiovascular and nervous system drugs. Drug
research in neonates should receive high priority to guarantee safe and appropriate medicines and optimal treatment.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Most drugs for neonates are prescribed off-label and the evidence for use is limited due to a scarcity of clinical trials on
efﬁcacy, dosage and safety.
• Considerable variation is observed between Dutch NICUs both regarding the number of antibiotics and the total dosage.
WHAT THIS STUDY ADDS
• The prescription of nervous system and cardiovascular drugs is highly variable between NICUs. These differences become
larger with decreasing postmenstrual age, although the proportion of off-label prescriptions in relation to neonatal age
decreased.
• Despite the new FDA and EMA drug legislation, many drugs are still used off-label and the variability in drug prescriptions
reﬂects the lack of evidence on drug use, especially in the smallest newborns.
• Consensus meetings on the treatment of common diseases and development of (inter)national guidelines should receive
the highest priority.
Introduction
Infants in the neonatal intensive care unit (NICU) are ex-
posed to a large number of drugs. Most drugs are off-label
for neonates and evidence for use in this population is sparse,
due to a limited number of clinical trials on efﬁcacy, dosage
and safety [1, 2]. These knowledge gaps are prone to large dif-
ferences in interpretation of available evidence and will con-
sequently be translated into different drug therapies
described in local treatment protocols and neonatal practice.
Previous studies have described drug prescriptions during
infancy, reporting a large proportion of off-label drug use
[2–7]. The proportion of off-label prescribed drugs increases
with decreasing age. Therefore, the most vulnerable paedi-
atric group – preterm infants – has the highest exposure
to drugs that are insufﬁciently documented [2]. In neonatal
care, almost all patients are exposed to at least one off-label
or non-approved drug during admission. Off-label use of
drugs has been associated with the risk of adverse drug re-
actions [8]. To improve paediatric drug therapy, new legisla-
tion was introduced more than a decade ago in the United
States with the Pediatric Research Equity Act in 2003 [9],
the Food and Drug Administration Reauthorization Act of
2017 [10], and in the European Union with the Paediatric
Regulation in 2006 [11] to encourage paediatric drug re-
search in the pre- and post-marketing phase. However,
these have not yet led to increased licensing [12, 13].
We aimed to investigate the differences in currently pre-
scribed drugs between neonatal intensive care units (NICUs)
in the Netherlands, and to study the off-label proportions,
as well as drug-class and age-related differences.
Methods
Patients and setting
In this retrospective cohort, all patients with an admission
date between 1 September 2014 and 31 August 2015 to one
of the four participating Dutch level III NICUs (Radboud
University Medical Center Nijmegen, Maastricht University
Medical Center Maastricht, Máxima Medical Center
Veldhoven and Sophia Children’s Hospital Rotterdam) were
eligible for inclusion. The study was conducted according to
Good Clinical Practice and the Declaration of Helsinki.
Definitions and drug classification
A prescription was deﬁned as a patient for whom a speciﬁc
drug was prescribed during admission to the NICU, regardless
of how often it was prescribed and of the route of administra-
tion. Patient days were deﬁned as the sum of treatment days
of each drug during admission to the NICU, which was calcu-
lated per patient and as a total. All drugs were classiﬁed in ac-
cordance with the Anatomical Therapeutic Chemical (ATC)
classiﬁcation system.
The deﬁnition by Neubert et al. for “off-label use” was ap-
plied, meaning ‘all uses of a marketed drug not detailed in the
summary of product characteristics (SmPC) including thera-
peutic indication, use in age-subsets, appropriate strength
(dosage), pharmaceutical form and route of administration’
[14]. However, the on/off-label status could be assessed only
for the active substance in relation to age-subsets, as informa-
tion concerning dosage, route of administration, indication,
drug preparation and formulation, could not be collected
from all four hospitals. Therefore, on/off-label status in rela-
tion to neonatal age (<1 month after birth) was assessed ac-
cording to the SmPC, which was consulted via the Dutch
Medicines Evaluation Board (www.cbg-meb.org, accessed on
12 October 2017). The status of a drug was considered on-
label if an SmPC for that active substance describes an indica-
tion that includes infants below 1month of age, which is also
the case if the drug is indicated for children in general.
Data collection
All four hospitals prescribed drugs using a computerized phy-
sician order entry system. Patient characteristics and drug
prescriptions were retrieved from the electronical medical
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records of each hospital. Data were collected on date of ad-
mittance, birth date, gestational age, birthweight, gender,
survival, drugs administered, and date and duration of drug
administration until death or discharge from the NICU. We
excluded ATC class ‘Q’ of veterinary drugs. We also excluded
electrolytes, total parenteral nutrition, Dutch national health
care system vaccines, supportive dermatological products
(not containing a drug), and contrast media. We followed
the guidelines in the Reporting of Studies Conducted using
Observational Routinely Collected Data (RECORD) state-
ment to report our study [15].
Data processing and statistical analysis
Data from the four NICUs were combined for the overall anal-
yses of neonatal prescriptions. The prescription frequency
was ranked, together with an analysis of the proportion of
prescriptions that were off-label in relation to neonatal age.
For comparison of the NICU prescriptions, patients were clas-
siﬁed into ﬁve different postmenstrual age groups at start of
drug use, because gestational age groups would be con-
founded by drug use at a later postnatal age: <26 weeks,
26–28 weeks, 28–32 weeks, 32–37 weeks and term neonates
≥37 weeks. Exposure to drugs was deﬁned as either the absolute
number of prescriptions or expressed per 1000 infants. Variabil-
ity in prescribed drugs per ATC class between NICUs was quan-
tiﬁed by calculating the range of total prescriptions per ATC
class per 1000 patients between NICUs. This range was used to
select the ATC classes for further investigation. All data were
stored and analysed in SPSS Statistics version 21 (IBM, Armonk,
NY,USA), using the non-parametric Kruskal–Wallis test for con-
tinuous variables and Pearson’s χ2 test for nominal variables,
with a P-value of <0.05 for signiﬁcance.
Treatment protocol comparison
Four common indications for drug use in neonatal care were
selected to compare the drugs and their suggested order as
written in the treatment protocols of the four NICUs. This
could give more insight into possible causes for differences
in drug prescriptions. The selected indications were pain, in-
tubation, convulsions and hypotension.
Results
During the one-year period, 1491 neonates were included in
the study with a total of 32 182 patient days, and a median
gestational age of 32+5 weeks (IQR: 29+6–37+6 weeks). Theme-
dian birth weight of all neonates was 1865 g (IQR: 1253–
3000 g), of which 14.5% had an extremely low birth weight
(ELBW; <1000 g). The median duration of admission to the
NICU was 12 days (IQR: 5–32 days). Data on post menstrual
age (PMA) at discharge was missing in six cases. Gestational
age, birth weight, duration of admission to the NICU, and
postmenstrual age at discharge were all signiﬁcantly different
between the four hospitals (Table 1).
Overall prescription of drugs and off-label use
in relation to neonatal age
In total, 181 different drugs were prescribed 10 895 times,
of which 23% was off-label in relation to neonatal age (see
Supporting Information File S1 for on-label age-range in
SmPC). The proportion of off-label prescriptions in rela-
tion to neonatal age increased with PMA at start of drug
therapy: 19% for infants with PMA at start below 32
weeks, 26% for infants with PMA between 32 and 37
weeks, and 29% above 37 weeks PMA. During admission,
54% of the neonates were exposed to at least one off-label
drug. The median number of prescribed drugs per patient
was ﬁve (IQR: 3–10). This was signiﬁcantly different be-
tween hospitals varying from a median of four to seven
drugs per patient.
The ATC class with the most frequently prescribed drugs
was anti-infective drugs with a total of 3161 prescriptions
(29%), of which 4% was off-label in relation to neonatal age
(Figure 1, Table 2). The second largest ATC class was the
nervous system drugs with 2500 prescriptions (23%) of
which 31% was off-label in relation to neonatal age. The
drug class of blood and blood-forming organs was the third
largest with 1386 prescriptions (13%). However, this result
was confounded since 54% of these prescriptions concerned
phytomenadione prescribed as supplementary vitamin in-
stead of the labelled indication as an antidote to anticoagu-
lant drugs of the coumarin type. The large proportion of
28% off-label prescriptions was caused by heparin for 86%,
which was indicated for arterial catheter patency.
Alimentary tract and metabolism drugs were fourth largest
with 1327 prescriptions (12%), 17% of which was off-label
in relation to neonatal age. Cardiovascular drugs were the
ﬁfth largest class with 958 prescriptions (9%), of which
30% was off-label in relation to neonatal age, for 84% due
to dopamine and noradrenaline. The sixth largest ATC class
was the respiratory drugs with 36% off-label prescriptions,
of which 76% was accounted for by xylometazoline and
doxapram.
Table 2 provides themost prescribed drugs overall and off-
label in all NICUs, which overall were, in rank order,
phytomenadione, cholecalciferol, caffeine, amoxicillin, gen-
tamicin, tobramycin, benzylpenicillin, paracetamol, surfac-
tant and morphine. Of these, none are off-label in relation
to neonatal age.
Differences in drug use between NICUs
The largest differences between NICUs were found for ner-
vous system drugs, with total prescriptions between NICUs
ranging 919–2278 per 1000 patients followed by 554–1465
for blood and blood-forming organs, and 238–952 for
cardiovascular system drugs, respectively (Figure 1). As 86%
of the range of prescribed drugs from blood and blood-
forming organs is caused by heparin and phytomenadione,
cardiovascular and nervous system drugs were considered
most interesting for a more extensive comparison
(Figure 2).
Cardiovascular drug prescriptions differed between the
four NICUs (Table 3), and with PMA (Figure 3A). Table 3
shows that the prescription of cardiovascular drugs varied
from none to six different agents between the different
NICUs in infants with PMA below 26 weeks. Dopamine expo-
sure for those neonates was high in two NICUs, where an-
other NICU showed larger variety of other haemodynamic
agonists for these preterm infants, i.e. dobutamine and
Large differences in drug use between NICUs
Br J Clin Pharmacol (2018) 84 1313–1323 1315
adrenaline. Furthermore, nervous system drugs showed large
variety (Figure 3B, Table 4). Interesting differences included
the variable use of propofol, levetiracetam and diuretics
between NICUs for all PMAs. Prescriptions of paracetamol
and phenobarbital were particularly different in the youngest
infants.
Figure 1
Total number of prescriptions and proportion off-label in each Anatomical Therapeutic Chemical (ATC) groupIn total, 10 895 prescriptions of 181
different drugs were retrieved, of which 23% was off-label in relation to neonatal age. * Range of total prescriptions per ATC class per 1000 pa-
tients between NICUs.
Table 1
Baseline characteristics of hospitalized neonates in four different NICUs in the Netherlands
NICU 1 NICU 2 NICU 3 NICU 4 p value Total/overall
Number of beds 18 15 13 31
Number of patients given drugs 314 353 223 601 1491
Male gender (%) 60 59 55 58 0.615a 58
Gestational age (weeks+days) 31+5 (29+2–35+5) 33+2 (30+2–38+0) 34+6 (30+5–38+3) 32+2 (29+4–37+5) <0.001b 32+5 (29+6–37+6)
<26 weeks (%) 17 (5.4) 15 (4.3) 8 (3.6) 39 (6.5) 0.001c 79 (5.3)
26–28 weeks (%) 33 (10.5) 32 (9.1) 15 (6.7) 59 (9.8) 139 (9.3)
28–32 weeks (%) 112 (35.7) 96 (27.3) 51 (22.9) 185 (30.8) 444 (29.8)
32–37 weeks (%) 82 (26.1) 88 (25.0) 53 (23.8) 139 (23.2) 362 (24.3)
≥ 37 weeks (%) 70 (22.3) 121 (34.4) 96 (43.0) 178 (29.6) 465 (31.2)
Birth weight (g) 1695 (1228–2613) 2012 (1350–3091) 2100 (1370–3120) 1800 (1200–2970) 0.007b 1865 (1253–3000)
ELBW (%) 48 (15.3) 51 (14.4) 22 (9.9) 95 (15.8) 0.214c 216 (14.5)
Number of days at NICU 24 (8–47) 12 (6–30) 12 (5–25) 7 (4–17) <0.001b 12 (5–32)
PMA at discharge 37+2 (35+4–39+6) 36+6 (33+0–40+3) 38+1 (35+0–40+5) 35+0 (32+1–39+3) <0.001b 36+5 (33+2–40+0)
Total patient days 9789 7769 4716 9908 32 182
Total prescriptions 2216 3371 1143 4165 10 895
Drugs per patient 5 (3–10) 7 (4–14) 4 (2–6) 5 (3–8) <0.001b 5 (3–10)
Patient days on drugs 28 (12–80) 36 (15–98) 18 (7–52) 13 (6–43) <0.001b 21 (8–71)
%OL in relation to neonatal age 21 29 11 23 <0.001b 23
Data presented as median (IQR).
aχ2 test
bKruskal–Wallis one-way analysis
cχ2 for distributions in all strata of gestational ages in four NICUs
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Treatment protocol comparison
Table 5 gives an overview of the drugs and the order in which
they should be prescribed according to the local treatment
protocols in the different NICUs for the four selected indica-
tions per gestational age groups.
Discussion
We evaluated drug prescriptions between NICUs for a period
of one year and found that a considerable percentage of the
drugs are still used off-label and that large differences exist
in drug prescriptions between the four NICUs. The largest
variability was found for drug classes with the highest propor-
tion of off-label drugs in relation to neonatal age, i.e. cardio-
vascular and nervous system drugs. These differences
became larger with decreasing PMA, although the proportion
of off-label prescriptions became smaller. Despite the new
FDA and EMA drug legislations, many drugs are still used
off-label and the variability in drugs prescriptions reﬂects
the lack of evidence on drug use, especially in the smallest
newborns.
Table 2
Most frequently prescribed drugs per 1000 neonates
No All drugs Prescriptions No
Off-label drugs in relation
to neonatal age Prescriptions
1 Phytomenadione 668 1 Heparin 219
2 Cholecalciferol 521 2 Fentanyl 193
3 Caffeine 480 3 Propofol 117
4 Amoxicillin 375 4 Dopamine 109
5 Gentamicin 375 5 Phenobarbital 91
6 Tobramycin 302 6 Hydrocortisone 79
7 Benzylpenicillin 287 7 Xylometazoline 68
8 Paracetamol 273 8 Miconazole 66
9 Surfactant 251 9 Phenylephrine + Tropicamide 57
10 Morphine 247 10 Norepinephrine 53
11 Heparin 219 11 Insulin 50
12 Fentanyl 193 12 Meropenem 43
13 Amoxicillin+ clavulanic acid 165 13 Dexamethasone 42
14 Midazolam 148 14 Doxapram 42
15 Atropine 137 15 Phenylephrine 38
16 Flucloxacillin 133 16 Chloralhydrate 30
17 Rocuronium 133 17 Ranitidine 27
18 Vancomycin 132 18 Levetiracetam 25
19 Furosemide 130 19 Cefazolin 15
20 Propofol 117 20 Cisatracurium 15
21 Dopamine 109 21 Ursodeoxycholic acid 15
22 Ceftazidime 95 22 Antitrombin 14
23 Phenobarbital 91 23 Esketamine 14
24 Ibuprofen 91 24 Tocopherol 13
25 Nystatin 81 25 Retinol 11
26 Hydrochlorothiazide 80 26 Trimethoprim 11
27 Spironolactone 80 27 Levomepromazine 10
28 Hydrocortisone 79 28 Sildenaﬁl 10
29 Dobutamine 70 29 Dornase 9
30 Xylometazoline 68 30 Lidocaine 9
Total of 10 985 prescriptions for 1491 patients. The number (No) indicates the ranking of prescribed drugs per 1000 patients
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Prescribed drugs
Of almost 11 000 drug prescriptions for neonates, 23% was
off-label in relation to neonatal age. Comparable proportions
of off-label prescriptions in relation to neonatal age were
found in the last decade by Neubert et al. with 38% in
Germany [16], Hsieh et al. with 35% in the USA [1], and
Cuzzolin et al. with 34% in Italy [17]. A comforting ﬁnding
was that the proportion of off-label prescriptions in relation
to neonatal age increased with PMA at start of drug therapy.
Therefore, the most vulnerable infants with the lowest PMA
were exposed to fewer off-label drugs than infants at higher
PMA. This might reﬂect the cautiousness of clinicians in
treating the most vulnerable patients. Dell’Aera et al. and
Avenel et al. also found a higher prevalence of off-label pre-
scriptions within the full-term neonates compared to the pre-
terms [5, 18].
Also comforting was the small proportion of off-label drug
prescriptions in relation to neonatal age (4%) in the largest
drug class of anti-infective drugs. On the other hand, the sec-
ond largest class concerned the nervous system drugs, of
which 31% was off-label in relation to neonatal age. These
ﬁndings are in agreement with those of Cuzzolin et al. and
Neubert et al. who also found that anti-infective drugs were
the largest ATC class prescribed with a proportion off-label
in relation to neonatal age of 24% and 11%, respectively
[16, 17]. For nervous system drugs, these studies found a
proportion of 67% and 56% of off-label prescriptions in re-
lation to neonatal age, which is comparable with our
results.
Nevertheless, off-label drug use does not necessarily im-
ply inadequate drug use, although this is generally sug-
gested [19]. Instead of referring to the label, adequate
drug use should be based on the level of evidence, with
an expert interpretation. Consequently, several sources
have been developed which are periodically updated and
released, such as the British National Formulary, Pediatric
Dosages by Lexicomp, Pediatric Injectable Drugs, and
Micromedex. Ceelie et al. reported on large differences be-
tween four commonly used paediatric drug formularies,
which indicates the challenges in the availability and
Figure 2
Range of prescriptions per drug per 1000 patients between NICUs in descending order. The top 35 drugs are listed in descending order of the
largest difference between minimum and maximum prescriptions.
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reliability of paediatric drug dosing guidelines in present
drug formularies [20]. Recently, in the Netherlands a con-
tinuously updated online paediatric formulary has been re-
leased – the Dutch Paediatric Formulary [21]. Despite the
valuable interpretation regarding dosages and safe drug
use, the sources mentioned above do not suggest which
drug to choose for certain indications and therefore do
not help to reduce the differences in prescriptions between
physicians and hospitals.
Comparing NICUs
Large differences between NICUs were found in neonatal
drug use. Drug classes with a high proportion of off-label drug
prescriptions in relation to neonatal age showed the largest
differences between NICUs, i.e. cardiovascular and nervous
system drugs. Also, these ATC classes, together with ATC class
blood and blood-forming organs, showed the largest range of
total prescriptions per ATC class per 1000 patients between
NICUs. As the high rank of blood and blood-forming organs
was driven by heparin and phytomenadione alone, this class
was of limited interest for further comparison.
The large differences among cardiovascular drugs
strengthen the alarmingmessage of a severe lack in paediatric
documentation, which has been reported by Bajcetic et al.
[22] and Pasquali et al. [23]. Nervous system drugs also
showed large variability, which may be a reﬂection of the var-
iation in drugs mentioned in pain treatment protocols of
these four NICUs. This may be explained by the worldwide
discussion on the neurodevelopmental safety of nervous sys-
tem drugs such as opioids, paracetamol and benzodiazepines
in the preterm brain [24]. A comparable discussion accounts
for the choice of premedication for intubation [25–27]. This
can be recognized in treatment protocols in our study, choos-
ing either an opioid with a muscle relaxant, or propofol.
Table 3
Cardiovascular drug prescriptions according to PMA (per 1000 neonates per PMA group)
NICU 1 NICU 2 NICU 3 NICU 4
PMA Drug No Drug No Drug No Drug No
<26 Dopamine 353 Dopamine 467 Dobutamine 231
Norepinephrine 59 Dopamine 154
Epinephrine 77
Hydrochlorothiazide 77
Spironolactone 77
Furosemide 26
26 < 28 Dopamine 273 Dopamine 156 Furosemide 67 Furosemide 339
Furosemide 242 Furosemide 125 Dobutamine 254
Hydrochlorothiazide 91 Norepinephrine 63 Hydrochlorothiazide 237
Spironolactone 91 Epinephrine 31 Spironolactone 237
Dobutamine 61 Dobutamine 31 Dopamine 153
Epinephrine 30 Milrinone 31 Epinephrine 85
28 < 32 Furosemide 107 Furosemide 156 Furosemide 157 Furosemide 205
Dopamine 63 Dopamine 146 Hydrochlorothiazide 78 Hydrochlorothiazide 184
Epinephrine 27 Norepinephrine 94 Spironolactone 78 Spironolactone 184
Norepinephrine 27 Hydrochlorothiazide 42 Dobutamine 114
Hydrochlorothiazide 18 Spironolactone 42 Dopamine 97
Spironolactone 18 Dobutamine 31 Epinephrine 92
32 < 37 Furosemide 98 Dopamine 170 Hydrochlorothiazide 113 Furosemide 151
Dopamine 85 Norepinephrine 148 Spironolactone 113 Hydrochlorothiazide 122
Hydrochlorothiazide 85 Furosemide 125 Furosemide 75 Spironolactone 122
Spironolactone 85 Hydrochlorothiazide 34 Metoprolol 19 Dobutamine 94
Dobutamine 24 Spironolactone 34 Epinephrine 58
Norepinephrine 24 Epinephrine 23 Dopamine 58
≥37 Dopamine 100 Dopamine 289 Furosemide 63 Dobutamine 129
Hydrochlorothiazide 71 Norepinephrine 248 Hydrochlorothiazide 52 Epinephrine 84
Spironolactone 71 Furosemide 215 Spironolactone 52 Dopamine 56
Norepinephrine 57 Milrinone 149 Digoxine 21 Furosemide 51
Epinephrine 43 Alprostadil 116 Propranolol 10 Alprostadil 45
Alprostadil 29 Dobutamine 99 Hydrochlorothiazide 39
The top ﬁve prescribed cardiovascular drugs are shown for every PMA group.
NICU, neonatal intensive care unit; PMA, postmenstrual age
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Mehler et al. studied analgesic and sedative drug use in very
low birth weight infants in German NICUs and reported large
differences, as well as many changes over time in analgesic
and sedative treatment [28]. On the other hand, the treat-
ment protocol of neonatal convulsions showed less differ-
ences between NICUs, which seems to be the result of an
existing national guideline [29]. Even though all mentioned
drugs in the guideline were off-label for treatment of convul-
sions in neonates, this publicly accessible expert opinion ap-
pears to reduce different interpretations of sparse evidence.
Liem et al. reported a comparable approach for antibiotic
drugs alone and found considerable variation between Dutch
NICUs in the number of different antibiotics used and in the
total dosage of antibiotics [30]. This heterogeneity indicates
that empirical antibiotic treatment varies among NICUs and
there are currently no consensus guidelines regarding the
choice of empirical antibiotics.
Although all four participating NICUs were level 3, con-
siderable differences were found in the general descriptives
between the NICUs; i.e. duration of admission, gestational
ages and speciﬁc treatments (surgery, extracorporeal mem-
brane oxygenation). These may partly explain the large vari-
ability in prescribed drugs between NICUs. Another cause
for differences in drug use concerns the steps by which new
evidence is adapted to clinical care, which may depend on
local expert opinions.
Our multicentre comparison of drug use in NICUs pro-
vides a unique view of neonatal pharmacology in practice
but is limited by some assumptions. First, our data did not al-
low comparison of NICUs with respect to drug dosages,
routes of administration, speciﬁc products or preparation of
drugs for administration. Apart from judging whether a drug
is registered for use in neonatal age, each of these items could
also have been related to the label if the data were available.
Second, since practically all drugs were ﬁrst labelled for an
adult indication, their ATC code was often incorrect with
respect to their use in current neonatal practice. Even for
drugs where the neonatal indication has been added to the
label, their ATC code remains as primarily marketed. This
concerns, for example, sildenaﬁl, ibuprofen, caffeine and
phytomenadione. Third, differences in local decision-making
practice determines treatments and drug use. In a smaller
NICU it may be easier to reach consensus than in a larger
NICU. Fourth, data was retrospectively collected from differ-
ent prospective electronic health record systems, which may
have caused some differences in deﬁnitions used for data out-
put. Fifth, our ﬁndings from a single country cohort cannot
easily be compared to other countries or reports, as the con-
tent of the SmPCs may be different between countries, and
various deﬁnitions for off-label status have been used, which
has also been shown by Aronson et al. [31]. Sixth, if the SmPC
mentioned an indication for infants in general without men-
tioning an age range, this was considered to also include neo-
nates and therefore on-label in relation to neonatal age (see
Supporting Information File S1). Nevertheless, physicians
would not feel safe to prescribe these drugs in clinical practice
based on this information, knowing that a general dosage for
infants is not optimal and safe for (preterm) neonates. How-
ever, if these drugs, with an on-label status for infants with-
out mentioning an age range, were to be considered off-
label in relation to neonatal age instead, the overall propor-
tion of off-label prescriptions in our cohort increases from
Figure 3
Exposure of preterm neonates in four NICUs to (A) cardiovascular and (B) nervous system drugs at different PMAs. The number of cardiovascular
drug prescriptions is expressed per 1000 patients in each PMA group. NICU, neonatal intensive care unit; PMA, postmenstrual age
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23% to 41%. This is mainly due to changes in the ATC groups;
cardiovascular drugs (from 30% to 94% off-label), anti-
infectives (from 4% to 24% off-label), and nervous system
drugs (from 31% to 46% off-label). In addition, an indication
and dosage for neonates in the SmPC rarely differentiates for
gestational age. As the deﬁnition of a ‘neonate’ is limited to a
newborn infant during its ﬁrst 30 days of life, without refer-
ring to a certain gestational age, we considered neonates to
be term as well preterm newborn infants. Nevertheless, on-
label in relation to neonatal age should not necessarily mean
on-label for all gestational ages.
Future suggestions
Our study shows that there is great variability in the drug pre-
scriptions for neonates in NICUs. Little consensus has been
reached on these drugs, and therefore expert interpretation of
current evidence and future research should be prioritized.
New investigator-initiated research is urgently required as
there is little beneﬁt to pharmaceutical companies in incorpo-
rating new ﬁndings in paediatrics, which has led to few drug-
labelling changes made under paediatric legislation, including
neonates [12]. Nevertheless, pharmacological trials involving
neonates deal with multiple challenges. Appropriate dosing is
Table 4
Nervous system drug prescriptions according to PMA (per 1000 neonates per PMA group)
NICU1 NICU2 NICU3 NICU4
PMA Drug No Drug No Drug No Drug No
<26 Caffeine 647 Caffeine 667 Caffeine 750 Caffeine 923
Fentanyl 529 Morphine 400 Paracetamol 125 Propofol 462
Morphine 176 Fentanyl 333 Morphine 231
Paracetamol 114 Midazolam 133 Fentanyl 103
Paracetamol 25 Midazolam 77
Phenobarbital 51
26 < 28 Caffeine 970 Caffeine 844 Caffeine 800 Caffeine 864
Fentanyl 394 Fentanyl 469 Paracetamol 267 Propofol 492
Paracetamol 333 Morphine 281 Fentanyl 200 Morphine 305
Morphine 273 Midazolam 156 Morphine 67 Fentanyl 186
Phenobarbital 91 Paracetamol 125 Phenobarbital 67 Midazolam 119
Midazolam 61 Phenobarbital 94 Midazolam 67 Phenobarbital 102
28 < 32 Caffeine 857 Caffeine 927 Caffeine 902 Caffeine 724
Fentanyl 304 Fentanyl 317 Paracetamol 78 Propofol 314
Paracetamol 259 Morphine 238 Fentanyl 59 Morphine 195
Morphine 170 Paracetamol 222 Methadone 59 Fentanyl 108
Propofol 27 Midazolam 95 Phenobarbital 39 Midazolam 81
Midazolam 18 Phenobarbital 63 Midazolam 39 Phenobarbital 49
32 < 37 Paracetamol 427 Morphine 364 Caffeine 566 Caffeine 403
Caffeine 378 Paracetamol 352 Paracetamol 226 Morphine 266
Morphine 134 Caffeine 341 Etomidate 57 Propofol 252
Fentanyl 122 Fentanyl 307 Fentanyl 57 Paracetamol 209
Phenobarbital 98 Midazolam 182 Midazolam 38 Fentanyl 173
Propofol 98 Chloralhydrate 80 Dexmedetomidine 19 Midazolam 165
>37 Paracetamol 557 Morphine 686 Paracetamol 396 Paracetamol 309
Morphine 257 Paracetamol 512 Phenobarbital 73 Midazolam 281
Phenobarbital 157 Midazolam 504 Caffeine 63 Morphine 253
Midazolam 157 Fentanyl 388 Fentanyl 31 Phenobarbital 185
Propofol 114 Phenobarbital 231 Midazolam 31 Levetiracetam 129
Chloralhydrate 100 Chloralhydrate 149 Morphine 21 Propofol 79
The top ﬁve prescribed nervous system drugs are shown for every PMA group.
NICU, neonatal intensive care unit; PMA, postmenstrual age
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hampered by the rapid physiological changes occurring at this
stage of development. The selection of proper end-points and
biomarkers is complicated by the limited knowledge of the
pathophysiology of the speciﬁc diseases of infancy. Coppini
et al. have addressed possible perspectives to stimulate research
in neonates and infants [32]. Furthermore, as evidence on
pharmacological treatment of neonates remains thin, more
(inter)national guidelines on treatment of common indica-
tions should be published, following the successful example
of the guideline for neonatal convulsions.
Conclusion
We showed that drugs used for neonatal care differed impor-
tantly between four Dutch level 3 NICUs. Our ﬁndings form
a valuable contribution to the several pooled prescription
data analyses of multiple NICUs that have been reported.
The drug classes with the highest proportion of off-label
drugs in relation to neonatal age showed the largest differ-
ences between NICUs, i.e. cardiovascular and nervous system
drugs. We believe that drug research in neonates should have
high priority to ensure the use of safe and appropriate drug
therapy in newborns.
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